Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
about
Limited Effect of Chronic Valproic Acid Treatment in a Mouse Model of Machado-Joseph DiseaseThe use of psychiatric drugs and worsening body mass index among inpatients with schizophreniaComparison of the metabolic syndrome risk in valproate-treated patients with epilepsy and the general population in Estonia.Anticonvulsive effect of paeoniflorin on experimental febrile seizures in immature rats: possible application for febrile seizures in children.Valproic Acid as a potentiator of metabolic syndrome in institutionalized residents on concomitant antipsychotics: fat chance, or slim to none?Role of isovaleryl-CoA dehydrogenase and short branched-chain acyl-CoA dehydrogenase in the metabolism of valproic acid: implications for the branched-chain amino acid oxidation pathway.Possible association between moderate intellectual disability and weight gain in valproic acid-treated patients with epilepsyConserved valproic-acid-induced lipid droplet formation in Dictyostelium and human hepatocytes identifies structurally active compounds.High-fat diet-induced obesity exacerbates kainic acid-induced hippocampal cell death.Association of LEPR and ANKK1 Gene Polymorphisms with Weight Gain in Epilepsy Patients Receiving Valproic Acid.Anticonvulsant Efficacy in Sturge-Weber SyndromeEffect of chronic valproic Acid treatment on hepatic gene expression profile in wfs1 knockout mouse.Histone deacetylase (HDAC) inhibition as a novel treatment for diabetes mellitus.The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders.Epigenetics of insulin resistance: an emerging field in translational medicine.Hepatic steatosis and steatohepatitis: Are they really two distinct entities?Valproic acid and nonalcoholic fatty liver disease: A possible association?Common Medications Which Lead to Unintended Alterations in Weight Gain or Organ Lipotoxicity.Diabetes and Schizophrenia.Drug-induced obesity and its metabolic consequences: a review with a focus on mechanisms and possible therapeutic options.Comparative Effect of Divided Doses of Adult Solid and Liquid Oral Formulations of Antiepileptic Drugs in the Management of Pediatric Epilepsy.Cytochrome P450 2C19 polymorphisms and valproic acid-induced weight gain.Weight change associated with antiepileptic drugs.Weight and fat distribution in patients taking valproate: a valproate-discordant gender-matched twin and sibling pair study.A longitudinal study of the association between the GNB3 C825T polymorphism and metabolic disturbance in bipolar II patients treated with valproate.Diabetes mellitus onset in geriatric patients: does long-term atypical antipsychotic exposure increase risk?Valproate ameliorates thioacetamide-induced fibrosis by hepatic stellate cell inactivation.Lysine deacetylase inhibition attenuates hypertension and is accompanied by acetylation of mineralocorticoid receptor instead of histone acetylation in spontaneously hypertensive rats.
P2860
Q28550502-2BBE2931-3CD1-48AA-A93D-4C533F734516Q33718231-58A2A574-9B67-45BE-9DCE-055595E71189Q33982437-1923C3F2-9200-4E71-B702-41D2391D1C8EQ34391122-DFA5F823-5D2A-445F-B8B5-B28D9F980B9BQ35042426-406BD5F7-A3E8-4ED7-8639-82E776922B64Q35079545-0E86107D-E03C-4ADE-9C20-E4F56FBC6C45Q35427844-9061E429-F6C1-4B26-B81C-63BB2BC5844AQ35794579-BBCA5900-B7CF-4D0D-B041-895C2AA4680EQ35827711-6EF7741E-9688-4CB0-91DE-F1D329065056Q35965897-1901ECFC-BA69-42E1-9AB4-276CA8470F65Q37090127-7AFD5E02-BCDD-47F3-A53F-E0206A3CF98EQ37715873-9D0DE25D-F47D-4A28-B1DA-B4F6EE5A32A1Q37832964-769DE12C-E429-4718-B1E4-A8917DA1172CQ38012489-C903D3F8-99C2-45F9-B436-9625EC0C2708Q38073159-DFE45155-37E7-4CBB-B2D4-DAEFAAE4B423Q38224490-B5C46832-1F31-4239-B664-43ABAA11BE84Q38505408-EA406C0A-D12B-4482-A56C-93EE60808F6FQ38677949-B844843B-15FB-4479-9864-443ED9202410Q38709352-3FF65875-6938-4D99-ADD9-A5699901510FQ39404106-B9162A1F-5357-4B0B-9211-848A3BCBB047Q40963082-AFEF9AA9-B0DF-4F01-AE4F-7D855BF087DAQ41533636-1BB836BA-C74F-4DC0-BAA7-86E80280F114Q45783139-CE60D45E-408E-42C0-A3FB-0F98F81BD392Q47442417-19A8C9C5-4E14-4876-9329-77BF06A2FB74Q48064476-92E702A8-B6F5-4642-A284-425E690FC835Q48181164-5CE4FA98-9422-4E71-807E-3F5EAF995957Q50471854-1888E93C-23E7-4B2C-B5A8-2EDC26F602BEQ51464359-6EC6D0EB-19CF-4884-A60C-300800740C4B
P2860
Weight gain following treatment with valproic acid: pathogenetic mechanisms and clinical implications.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 06 September 2010
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Weight gain following treatmen ...... sms and clinical implications.
@en
Weight gain following treatmen ...... sms and clinical implications.
@nl
type
label
Weight gain following treatmen ...... sms and clinical implications.
@en
Weight gain following treatmen ...... sms and clinical implications.
@nl
prefLabel
Weight gain following treatmen ...... sms and clinical implications.
@en
Weight gain following treatmen ...... sms and clinical implications.
@nl
P2093
P2860
P1433
P1476
Weight gain following treatmen ...... sms and clinical implications.
@en
P2093
P2860
P304
P356
10.1111/J.1467-789X.2010.00800.X
P577
2010-09-06T00:00:00Z